New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 15, 2014
08:02 EDTCVMCEL-SCI receives $225K NIH research grant
CEL-SCI announced that it has been awarded a Phase I Small Business Innovation Research grant in the amount of $225K from the National Institute of Arthritis Muscoskeletal and Skin Diseases, which is part of the National Institutes of Health. The grant will fund the further development of CEL-SCIís LEAPS technology as a potential treatment for rheumatoid arthritis. The NIH grant was awarded based on preliminary data by Tibor Glantís team in collaboration with CEL-SCI showing that the administration of a proprietary peptide using CEL-SCI's LEAPS technology prevented the development, and lessened the severity, including inflammation, of experimental RA when it was administered after the disease was induced in the animals. This data was presented in May 2013 by Daniel Zimmerman, CEL-SCIís senior vice president of research, cellular immunology, at the symposium on ďTherapeutic Approaches to AutoimmunityĒ during the American Association of Immunologists 100th annual meeting in Honolulu, Hawaii.
News For CVM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
09:25 EDTCVMOn The Fly: Pre-market Movers
Subscribe for More Information
09:08 EDTCVMCEL-SCI prices $16M of common stock and warrants at 79c
Subscribe for More Information
08:29 EDTCVMFBR scuttled CEL-SCI offering after 'CEO meddling,' Feuerstein says
FBR scuttled its role in a CEL-SCI (CVM) offering due to "inappropriate CEO meddling," leaving Dawson James to be "brought on to salvage something," according to TheStreet's Adam Feuerstein citing a source. The Fly notes CEL-SCI announced last night a proposed offering of common stock and warrants, with no amount given and Dawson James Securities acting as the sole placement agent on a "best efforts" basis. IsoRay (ISR) tried to raise money yesterday too, Feuerstein reported on Twitter, citing an investor source.
May 21, 2015
18:49 EDTCVMOn The Fly: After Hours Movers
UP AFTER EARNINGS: Hewlett-Packard (HPQ), up 1%. ALSO HIGHER: Autobytel (ABTL), up 14.1% after acquiring Dealix Corporation and Autotegrity from CDK Global (CDK) for $25M and raising fiscal 2015 guidance... StemCells (STEM), up 2.5% after being initiated with a Buy at Cantor... PTC Therapeutics (PTCT), up 2.3% after a Benefit Assessment by Germany's Federal Joint Committee indicated that Translarna provided a benefit for ambulatory patients... CBOE Holdings (CBOE), up 1.6% after raising share repurchase authorization by $100M... Cypress Semiconductor (CY), up 1.2% after being initiated with a Buy at Mizuho. DOWN AFTER EARNINGS: Aeropostale (ARO), down 18.5%... Brocade (BRCD), down 2.1%... Marvell Technology (MRVL), down 2.9% after reporting quarterly results and departure of CFO. ALSO LOWER: Otonomy (OTIC), down 17.7% following report of Phase 2b topline data for OTO-104... Viggle (VGGL), down 18.8% after filing to sell common stock... CEL-SCI (CVM),down 2.7% after announcing a proposed offering of common stock and warrants.
16:35 EDTCVMCEL-SCI announces proposed offering of common stock, warrants, no amount given
Subscribe for More Information
May 13, 2015
09:00 EDTCVMCEL-SCI receives authorization to conduct Phase 3 Multikine trial in Italy
CEL-SCI Corporation announced that the Italian Medicines Agency has authorized the company to commence patient enrollment for its ongoing Phase 3 trial of its investigational immunotherapy Multikine in patients with advanced primary squamous cell carcinoma of the oral cavity/soft palate, a type of head and neck cancer. Italy is the 23rd country to authorize CEL-SCIís Phase 3 trial for patient enrollment. Having surpassed its originally planned milestone of receiving authorization to conduct the Phase 3 study from 21 countries, CEL-SCI is now aiming to expand the trial into a total of approximately 100 clinical centers in about 25 countries. As of April 30, 2015, 437 patients had been enrolled in the global Phase 3 study. The Multikine Phase 3 study is enrolling patients with advanced primary squamous cell carcinoma of the head and neck. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus standard of care vs. subjects who are treated with SOC only.
May 11, 2015
08:05 EDTCVMCEL-SCI receives authorization to conduct Phase 3 Multikine trial in Spain
Subscribe for More Information
May 8, 2015
17:03 EDTCVMCEL-SCI reports Q2 EPS (17c), consensus (11c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use